{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:06:47Z","timestamp":1792793207052,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA236814-01A1"],"award-info":[{"award-number":["1R01CA236814-01A1"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["3R01-CA236814-03S1"],"award-info":[{"award-number":["3R01-CA236814-03S1"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA272691-01"],"award-info":[{"award-number":["U54CA272691-01"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA272691-01"],"award-info":[{"award-number":["U54CA272691-01"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA180190"],"award-info":[{"award-number":["CA180190"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA180190"],"award-info":[{"award-number":["CA180190"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Myeloma Crowd Research Initiative Award, Paula and Rodger Riney Foundation, Myeloma Solution Fund, UAMS Winthrop P. Rockefeller Cancer Institute (WRCRI) Fund"},{"name":"Arkansas Breast Cancer Research Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment strategy with high response rates in myeloma. However, durable cures following anti-BCMA CAR-T cell treatment of myeloma are rare. One potential reason is that a small subset of minimal residual myeloma cells seeds relapse. Residual myeloma cells following BCMA-CAR-T-mediated treatment show less-differentiated features and express stem-like genes, including CD24. CD24-positive myeloma cells represent a large fraction of residual myeloma cells after BCMA-CAR-T therapy. In this work, we develop CD24-CAR-T cells and test their ability to eliminate myeloma cells. We find that CD24-CAR-T cells block the CD24-Siglec-10 pathway, thereby enhancing macrophage phagocytic clearance of myeloma cells. Additionally, CD24-CAR-T cells polarize macrophages to a M1-like phenotype. A dual-targeted BCMA-CD24-CAR-T exhibits improved efficacy compared to monospecific BCMA-CAR-T-cell therapy. This work presents an immunotherapeutic approach that targets myeloma cells and promotes tumor cell clearance by macrophages.<\/jats:p>","DOI":"10.1038\/s41467-024-44873-4","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:02:23Z","timestamp":1705680143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth"],"prefix":"10.1038","volume":"15","author":[{"given":"Fumou","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7877-9622","authenticated-orcid":false,"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-3838","authenticated-orcid":false,"given":"Visanu","family":"Wanchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzheng","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-6612","authenticated-orcid":false,"given":"Eric","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-0283","authenticated-orcid":false,"given":"Cody","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-3398","authenticated-orcid":false,"given":"Qing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2229-5511","authenticated-orcid":false,"given":"Siegfried","family":"Janz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-5078","authenticated-orcid":false,"given":"Gail","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-2973","authenticated-orcid":false,"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"44873_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh, R. H. & Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J. Clin. 73, 275\u2013285 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"44873_CR2","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/blood.2020008734","volume":"139","author":"E Kastritis","year":"2022","unstructured":"Kastritis, E., Terpos, E. & Dimopoulos, M. A. How I treat relapsed multiple myeloma. Blood 139, 2904\u20132917 (2022).","journal-title":"Blood"},{"key":"44873_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie, S. A. & Hill, G. R. Immunotherapy of multiple myeloma. J. Clin. Investig. 130, 1565\u20131575 (2020).","journal-title":"J. Clin. Investig."},{"key":"44873_CR4","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.3324\/haematol.2020.266858","volume":"106","author":"L Rasche","year":"2021","unstructured":"Rasche, L., Wasch, R., Munder, M., Goldschmidt, H. & Raab, M. S. Novel immunotherapies in multiple myeloma - chances and challenges. Haematologica 106, 2555\u20132565 (2021).","journal-title":"Haematologica"},{"key":"44873_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"44873_CR6","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","volume":"27","author":"L Xing","year":"2021","unstructured":"Xing, L. et al. BCMA-Specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression. Clin. Cancer Res. 27, 5376\u20135388 (2021).","journal-title":"Clin. Cancer Res."},{"key":"44873_CR7","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Usmani, S. Z. & Yong, K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 8, e446\u2013e461 (2021).","journal-title":"Lancet Haematol."},{"key":"44873_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh, P. J. & Chng, W. J. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 11, 84 (2021).","journal-title":"Blood Cancer J."},{"key":"44873_CR9","doi-asserted-by":"publisher","first-page":"215949","DOI":"10.1016\/j.canlet.2022.215949","volume":"553","author":"J Yang","year":"2023","unstructured":"Yang, J., Zhou, W., Li, D., Niu, T. & Wang, W. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Lett. 553, 215949 (2023).","journal-title":"Cancer Lett."},{"key":"44873_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple Myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"44873_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"44873_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 41, 1265\u20131274 (2023).","journal-title":"J Clin Oncol"},{"key":"44873_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3389\/fimmu.2020.01128","volume":"11","author":"E Garcia-Guerrero","year":"2020","unstructured":"Garcia-Guerrero, E., Sierro-Martinez, B. & Perez-Simon, J. A. Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma. Front. Immunol. 11, 1128 (2020).","journal-title":"Front. Immunol."},{"key":"44873_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).","journal-title":"Nat. Commun."},{"key":"44873_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"44873_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","volume":"34","author":"M D\u2019Agostino","year":"2020","unstructured":"D\u2019Agostino, M. & Raje, N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia 34, 21\u201334 (2020).","journal-title":"Leukemia"},{"key":"44873_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/jnci\/djz159","volume":"112","author":"M Gao","year":"2020","unstructured":"Gao, M. et al. Identification and characterization of tumor-initiating cells in multiple myeloma. J. Natl. Cancer Inst. 112, 507\u2013515 (2020).","journal-title":"J. Natl. Cancer Inst."},{"key":"44873_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.08.005","volume":"277","author":"N Ghosh","year":"2009","unstructured":"Ghosh, N. & Matsui, W. Cancer stem cells in multiple myeloma. Cancer Lett 277, 1\u20137 (2009).","journal-title":"Cancer Lett"},{"key":"44873_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar, K. M. et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 3, 490\u2013501 (2022).","journal-title":"Blood Cancer Discov."},{"key":"44873_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10555-016-9648-7","volume":"35","author":"CL Chaffer","year":"2016","unstructured":"Chaffer, C. L., San Juan, B. P., Lim, E. & Weinberg, R. A. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35, 645\u2013654 (2016).","journal-title":"Cancer Metastasis Rev."},{"key":"44873_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","volume":"134","author":"WH Khoo","year":"2019","unstructured":"Khoo, W. H. et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 134, 30\u201343 (2019).","journal-title":"Blood"},{"key":"44873_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li, W. et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp. Hematol. Oncol. 12, 44 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"44873_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cmet.2022.07.005","volume":"34","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder. Cell Metab. 34, 1088\u20131103.e1086 (2022).","journal-title":"Cell Metab."},{"key":"44873_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/jpm12081235","volume":"12","author":"E Panagiotou","year":"2022","unstructured":"Panagiotou, E., Syrigos, N. K., Charpidou, A., Kotteas, E. & Vathiotis, I. A. CD24: a novel target for cancer immunotherapy. J. Pers. Med. 12, 1235 (2022).","journal-title":"J. Pers. Med."},{"key":"44873_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392\u2013396 (2019).","journal-title":"Nature"},{"key":"44873_CR26","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1126\/science.1168988","volume":"323","author":"GY Chen","year":"2009","unstructured":"Chen, G. Y., Tang, J., Zheng, P. & Liu, Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323, 1722\u20131725 (2009).","journal-title":"Science"},{"key":"44873_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41568-019-0193-x","volume":"19","author":"CA Bradley","year":"2019","unstructured":"Bradley, C. A. CD24 - a novel \u2018don\u2019t eat me\u2019 signal. Nat. Rev. Cancer 19, 541 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"44873_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/bjc.1989.36","volume":"59","author":"A Smith","year":"1989","unstructured":"Smith, A. et al. Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. Br. J. Cancer 59, 174\u2013178 (1989).","journal-title":"Br. J. Cancer"},{"key":"44873_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/ijms20030660","volume":"20","author":"R Klapdor","year":"2019","unstructured":"Klapdor, R. et al. Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer. Int. J. Mol. Sci. 20, 660 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"44873_CR30","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip, B. et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood 124, 1277\u20131287 (2014).","journal-title":"Blood"},{"key":"44873_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-1441-9_1","volume":"2312","author":"A Okuma","year":"2021","unstructured":"Okuma, A. Generation of CAR-T cells by lentiviral transduction. Methods Mol Biol 2312, 3\u201314 (2021).","journal-title":"Methods Mol Biol"},{"key":"44873_CR32","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"44873_CR33","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.annonc.2021.07.018","volume":"32","author":"D Meyran","year":"2021","unstructured":"Meyran, D. et al. Early-phenotype CAR-T cells for the treatment of pediatric cancers. Ann. Oncol. 32, 1366\u20131380 (2021).","journal-title":"Ann. Oncol."},{"key":"44873_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10555-020-09943-1","volume":"40","author":"KS Opperman","year":"2021","unstructured":"Opperman, K. S., Vandyke, K., Psaltis, P. J., Noll, J. E. & Zannettino, A. C. W. Macrophages in multiple myeloma: key roles and therapeutic strategies. Cancer Metastasis Rev. 40, 273\u2013284 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"44873_CR35","doi-asserted-by":"publisher","first-page":"110595","DOI":"10.1016\/j.biopha.2020.110595","volume":"130","author":"F Krautter","year":"2020","unstructured":"Krautter, F. et al. Characterisation of endogenous Galectin-1 and -9 expression in monocyte and macrophage subsets under resting and inflammatory conditions. Biomed. Pharmacother. 130, 110595 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"44873_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah, E. et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat. Commun. 11, 2283 (2020).","journal-title":"Nat. Commun."},{"key":"44873_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","volume":"41","author":"Y Tang","year":"2022","unstructured":"Tang, Y. et al. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J. Exp Clin. Cancer Res. 41, 2 (2022).","journal-title":"J. Exp Clin. Cancer Res."},{"key":"44873_CR38","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan, Z. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 6, e521\u2013e529 (2019).","journal-title":"Lancet Haematol."},{"key":"44873_CR39","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J. Clin. Oncol. 40, 2246\u20132256 (2022).","journal-title":"J. Clin. Oncol."},{"key":"44873_CR40","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall, A. L. et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040\u20131047 (2015).","journal-title":"N. Engl. J. Med."},{"key":"44873_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12185-013-1293-0","volume":"97","author":"N Hosen","year":"2013","unstructured":"Hosen, N. Multiple myeloma-initiating cells. Int. J. Hematol. 97, 306\u2013312 (2013).","journal-title":"Int. J. Hematol."},{"key":"44873_CR42","first-page":"5264","volume":"52","author":"D Jackson","year":"1992","unstructured":"Jackson, D., Waibel, R., Weber, E., Bell, J. & Stahel, R. A. CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res. 52, 5264\u20135270 (1992).","journal-title":"Cancer Res."},{"key":"44873_CR43","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/bjc.2013.102","volume":"108","author":"AV Salnikov","year":"2013","unstructured":"Salnikov, A. V. et al. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br. J. Cancer 108, 1449\u20131459 (2013).","journal-title":"Br. J. Cancer"},{"key":"44873_CR44","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1158\/0008-5472.CAN-07-6463","volume":"68","author":"E Sagiv","year":"2008","unstructured":"Sagiv, E. et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 68, 2803\u20132812 (2008).","journal-title":"Cancer Res."},{"key":"44873_CR45","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/0008-5472.CAN-18-2839","volume":"79","author":"F Sun","year":"2019","unstructured":"Sun, F. et al. Anti-CD24 antibody-nitric oxide conjugate selectively and potently suppresses hepatic carcinoma. Cancer Res. 79, 3395\u20133405 (2019).","journal-title":"Cancer Res."},{"key":"44873_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/bjh.16158","volume":"188","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression. Br. J. Haematol. 188, 283\u2013294 (2020).","journal-title":"Br. J. Haematol."},{"key":"44873_CR47","doi-asserted-by":"publisher","first-page":"11283","DOI":"10.18632\/oncotarget.2207","volume":"5","author":"K Beider","year":"2014","unstructured":"Beider, K. et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4\/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 5, 11283\u201311296 (2014).","journal-title":"Oncotarget"},{"key":"44873_CR48","doi-asserted-by":"publisher","first-page":"24218","DOI":"10.18632\/oncotarget.4523","volume":"6","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma. Oncotarget 6, 24218\u201324229 (2015).","journal-title":"Oncotarget"},{"key":"44873_CR49","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/ijms19061801","volume":"19","author":"C Atri","year":"2018","unstructured":"Atri, C., Guerfali, F. Z. & Laouini, D. Role of human macrophage polarization in inflammation during infectious diseases. Int. J. Mol. Sci. 19, 1801 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"44873_CR50","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3109\/10428194.2013.778409","volume":"54","author":"F Asimakopoulos","year":"2013","unstructured":"Asimakopoulos, F. et al. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk. Lymphoma 54, 2112\u20132121 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"44873_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay, R. et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 11, 599\u2013613 (2021).","journal-title":"Cancer Discov."},{"key":"44873_CR52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.omto.2020.07.005","volume":"18","author":"A Klampatsa","year":"2020","unstructured":"Klampatsa, A. et al. Analysis and augmentation of the immunologic bystander effects of CAR T cell therapy in a syngeneic mouse cancer model. Mol. Ther. Oncolytics 18, 360\u2013371 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"44873_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"44873_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 34, 45\u201355 (2019).","journal-title":"Blood Rev."},{"key":"44873_CR55","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.10176","volume":"71","author":"MT Elghetany","year":"2002","unstructured":"Elghetany, M. T. & Patel, J. Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am. J. Hematol. 71, 348\u2013349 (2002).","journal-title":"Am. J. Hematol."},{"key":"44873_CR56","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/0306-4522(96)00042-5","volume":"73","author":"V Calaora","year":"1996","unstructured":"Calaora, V., Chazal, G., Nielsen, P. J., Rougon, G. & Moreau, H. mCD24 expression in the developing mouse brain and in zones of secondary neurogenesis in the adult. Neuroscience 73, 581\u2013594 (1996).","journal-title":"Neuroscience"},{"key":"44873_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/aja.1001980102","volume":"198","author":"T Shirasawa","year":"1993","unstructured":"Shirasawa, T. et al. Gene expression of CD24 core peptide molecule in developing brain and developing non-neural tissues. Dev. Dyn. 198, 1\u201313 (1993).","journal-title":"Dev. Dyn."},{"key":"44873_CR58","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1432-0436.1999.6440237.x","volume":"64","author":"DS Cram","year":"1999","unstructured":"Cram, D. S., McIntosh, A., Oxbrow, L., Johnston, A. M. & DeAizpurua, H. J. Differential mRNA display analysis of two related but functionally distinct rat insulinoma (RIN) cell lines: identification of CD24 and its expression in the developing pancreas. Differentiation 64, 237\u2013246 (1999).","journal-title":"Differentiation"},{"key":"44873_CR59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/cmi.2009.119","volume":"7","author":"X Fang","year":"2010","unstructured":"Fang, X., Zheng, P., Tang, J. & Liu, Y. CD24: from A to Z. Cell Mol. Immunol. 7, 100\u2013103 (2010).","journal-title":"Cell Mol. Immunol."},{"key":"44873_CR60","doi-asserted-by":"publisher","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","volume":"14","author":"R Velasco","year":"2023","unstructured":"Velasco, R., Mussetti, A., Villagran-Garcia, M. & Sureda, A. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern? Front. Neurol. 14, 1144414 (2023).","journal-title":"Front. Neurol."},{"key":"44873_CR61","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419\u2013432.e416 (2016).","journal-title":"Cell"},{"key":"44873_CR62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000046628","volume":"107","author":"M Yagci","year":"2002","unstructured":"Yagci, M., Sucak, G. T., Akyol, G. & Haznedar, R. Hepatic failure due to CD3+ plasma cell infiltration of the liver in multiple myeloma. Acta Haematol. 107, 38\u201342 (2002).","journal-title":"Acta Haematol."},{"key":"44873_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1158\/1078-0432.CCR-18-1435","volume":"25","author":"M Hao","year":"2019","unstructured":"Hao, M. et al. Gene expression profiling reveals aberrant T-cell marker expression on tumor cells of Waldenstrom\u2019s macroglobulinemia. Clin. Cancer Res. 25, 201\u2013209 (2019).","journal-title":"Clin. Cancer Res."},{"key":"44873_CR64","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"44873_CR65","doi-asserted-by":"publisher","first-page":"D870","DOI":"10.1093\/nar\/gkac947","volume":"51","author":"C Hu","year":"2023","unstructured":"Hu, C. et al. CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 51, D870\u2013D876 (2023).","journal-title":"Nucleic Acids Res."},{"key":"44873_CR66","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493\u2013506 (2020).","journal-title":"Nat. Cancer"},{"key":"44873_CR67","doi-asserted-by":"publisher","first-page":"e159527","DOI":"10.1172\/JCI159527","volume":"132","author":"D Gai","year":"2022","unstructured":"Gai, D. et al. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J. Clin. Investig. 132, e159527 (2022).","journal-title":"J. Clin. Investig."},{"key":"44873_CR68","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"44873_CR69","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","volume":"27","author":"C Sommer","year":"2019","unstructured":"Sommer, C. et al. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. Mol. Ther. 27, 1126\u20131138 (2019).","journal-title":"Mol. Ther."},{"key":"44873_CR70","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44873-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T17:08:56Z","timestamp":1705684136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44873-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44873"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-44873-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. and F.Z. are inventors on the patent application \u201cBispecific BCMA-CD24-CAR-T design\u201d, describing the therapeutic use of BCMA-CD24-CAR-T cells for the treatment of multiple myeloma. The patent number is pending. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"615"}}